Search details
1.
Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
Proc Natl Acad Sci U S A
; 119(38): e2202727119, 2022 09 20.
Article
in English
| MEDLINE | ID: mdl-36099300
2.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Br J Cancer
; 130(3): 476-482, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38135713
3.
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol
; 187: 105-112, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38759516
4.
PolyG-DS: An ultrasensitive polyguanine tract-profiling method to detect clonal expansions and trace cell lineage.
Proc Natl Acad Sci U S A
; 118(31)2021 08 03.
Article
in English
| MEDLINE | ID: mdl-34330826
5.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 24(2): 162-174, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36623515
6.
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
Gynecol Oncol
; 172: 29-35, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36931101
7.
Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials.
J Natl Compr Canc Netw
; 21(1): 27-32.e2, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36634612
8.
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Int J Gynecol Cancer
; 33(6): 982-987, 2023 06 05.
Article
in English
| MEDLINE | ID: mdl-37045546
9.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Article
in English
| MEDLINE | ID: mdl-31562800
10.
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol
; 164(2): 278-287, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34930617
11.
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol
; 164(2): 245-253, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34906376
12.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36273926
13.
Characterization of splice-altering mutations in inherited predisposition to cancer.
Proc Natl Acad Sci U S A
; 116(52): 26798-26807, 2019 Dec 26.
Article
in English
| MEDLINE | ID: mdl-31843900
14.
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Gynecol Oncol
; 162(2): 375-381, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34112513
15.
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Gynecol Oncol
; 163(1): 130-133, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34452747
16.
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecol Oncol
; 160(3): 786-792, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33375991
17.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34602290
18.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33752918
19.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34103386
20.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32359490